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ABSTRACT 
The objective of the present study was to evaluate acute oral toxicity, subchronic toxicity, and mutagenic poten-
tial of low molecular weight galactomannans based standardized fenugreek seeds extract (LMWGAL-TF) in la-
boratory animals rats as per Organization for Economic Co-operation and Development (OECD) guidelines. For 
the acute toxicity (AOT) study, LMWGAL-TF was orally administered to Sprague-Dawley (SD) rats at a dose of 
2000 mg/kg with vehicle control (VC) group (n = 5 per sex per group) as per OECD guideline no. 423. For the 
repeated dose toxicity study, the SD rats were orally administered with a daily oral dose of LMWGAL-TF 250, 
500 and 1000 mg/kg/day with VC group (n = 15 per sex) for a period of 90 days followed by a recovery period 
of 28 days as per OECD guideline no. 408. The effects on body weight, food and water consumption, organ 
weights with hematology, clinical biochemistry, and histology were studied. The mutagenic potential of LMW-
GAL-TF was tested using reverse mutation assay (AMES test, OECD guideline No. 471). The LMWGAL-TF 
did not show mortality or treatment-related adverse signs during acute (dose 2000 mg/kg) and subchronic (90-
days repeated dose 250, 500 and 1000 mg/kg) administration. The LMWGAL-TF showed oral lethal dose (LD50) 
more than 2000 mg/kg during AOT study. The dose of 1000 mg/kg was found as no observed adverse effect lev-
el (NOAEL) in rats during subchronic toxicity study. Furthermore, LMWGAL-TF did not show mutagenic po-
tential in vitro. In conclusion, LMWGAL-TF was found safe during acute and subchronic (90 days repeated 
dose) toxicity studies in rats with no mutagenicity. 
 
Keywords: Low molecular weight galactomannans, Fenugreek seed extract, acute oral toxicity, subchronic tox-
icity, mutagenicity, OECD guidelines 
 
 
 
 
INTRODUCTION 
Since ancient times, plants (or food) de-
rived natural products have commonly been 
used in folk medicine for the treatment of 
various ailments. The growing use of plant-
derived food supplements is accompanied by 
an increasing concern for their safety 
(Werner, 2014). Therefore, scientific data re-
lated to the safety evaluation of plant-derived 
food supplements has become crucial for 
validation of quality and safety claims for 
their safe human consumption (Govindara-
ghavan and Sucher, 2015).  
Because of a broad spectrum of therapeu-
tic benefits, the fenugreek (Trigonella 
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foenum-graecum L., family Fabaceae) seeds 
have received considerable attention as 
plant-derived food / nutritional supplement 
(Yadav and Baquer, 2014). Fenugreek seeds 
are documented in many traditional systems 
of medicine, such as Ayurveda, for the 
management of many chronic conditions. 
The modern scientific literature reported 
beneficial effects of fenugreek seeds powder 
and extract on glucose and fat metabolism in 
animal models and patients with diabetes 
mellitus (Roberts, 2011). Fenugreek seed de-
rived food supplement products including 
extracts have been explored successfully for 
many exercise physiology applications in-
volving healthy volunteers and patients 
(Basch et al., 2003; Thompson and Ernst, 
2003) including anabolic (Poole et al., 2010) 
and androgenic activities (Mokashi et al., 
2014; Wilborn et al., 2010). Safety of fenu-
greek seeds in human subjects has been re-
ported in many clinical studies and reviews 
(Basch et al., 2003; Poole et al., 2010; 
Thompson and Ernst, 2003).  
Recently, low molecular weight galac-
tomannans-based standardized fenugreek 
seed extract (LMWGAL-TF) showed prom-
ising and dose-dependent efficacy in an 
animal model of hyperglycemia and insulin 
resistance (Kandhare et al., 2015). In addi-
tion, LMWGAL-TF had demonstrated ana-
bolic ability without affecting hormonal sta-
tus in animals (Aswar et al., 2008) and the 
exercising individuals (Wilborn et al., 2008). 
However, safety information of LMWGAL-
TF using scientifically validated and interna-
tionally accepted guidelines is lacking. 
Therefore, we undertook the present work 
with an objective to evaluate the acute oral 
toxicity (AOT), 90-days repeated dose (sub-
chronic) toxicity and mutagenicity of 
LMWGAL-TF using well-accepted guide-
lines issued by Organization for Economic, 
Co-operation, and Development (OECD). 
 
MATERIALS AND METHODS 
Animals 
The Sprague-Dawley rats; 6-8 weeks old 
weighing 125-150 g of both sexes were used 
for acute and 90-day (subchronic) toxicity 
studies. The females were nulliparous and 
non-pregnant. The rats kept for seven days 
prior to dosing for acclimatization, cages 
were marked, and individual marking was 
made on fur for identification. Rats were on 
pelleted feed (Nav Maharashtra Chakan Oil 
Mills Ltd, Pune, India) and provided with 
pure potable water in glass bottles ad labium. 
The rats were maintained at ambient temper-
ature (20 ± 3° C), relative humidity (30-
70 %), and 10-15 air changes per hour with 
12 h: 12h of the dark and light cycle.  
All experiments complied with the 
OECD Guidelines for the testing of chemi-
cals (Organisation for Economic Co-
operation and Development, 1998) and 
Schedule Y in Drugs and Cosmetics Act (IInd 
Amendment) Rules, 2005, Ministry of 
Health and Family Welfare, Government of 
India. The protocol was approved by the In-
stitutional Animal Ethics Committee. 
 
The test compound 
The test compound, LMWGAL-TF, was 
supplied by Indus Biotech Private Limited 
(Pune, India) after preparation and character-
ization (HPLC and LC-MS) as per reported 
procedure (Kamble et al., 2013). LMWGAL-
TF is standardized fenugreek seed extract 
with 96.21 % water-soluble low molecular 
weight galactomannan containing oligosac-
charides. LMWGAL-TF is commercially 
available as Torabolic®. LMWGAL-TF was 
dissolved in distilled water for use in acute 
and sub-chronic studies in a dose volume of 
10 ml/kg body weight of rats. LMWGAL-TF 
solution was freshly prepared before admin-
istration. LMWGAL-TF solution in sterile 
water for injection was used for mutagenicity 
evaluation.  
 
Acute oral toxicity (AOT) study  
The acute toxicity study of LMWGAL-
TF was performed according to OECD 
guideline 423 (Organisation for Economic 
Co-operation and Development, 2002). The 
SD rats were grouped in 2 groups (5 
rats/sex/group) and treated with a single dose 
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as follows: G1 – Vehicle control (VC) (dou-
ble distilled water, 10 mL/kg, oral), and G2 
(LMWGAL-TF, 2000 mg/kg, oral.). The rats 
were observed daily for 14 days following 
administration for mortality and clinical 
signs of toxicity. On day 15, all animals were 
euthanized and underwent gross pathological 
examination for signs of toxicity via necrop-
sy. 
 
Repeated dose 90-day oral toxicity  
(Sub-chronic) study 
The study complies with the OECD 
Guideline for the testing of Chemicals No. 
408 (Organisation for Economic Co-
operation and Development, 1998). Based on 
median lethal dose (LD50) (2000 mg/kg) ob-
tained from AOT study, animals were orally 
administered daily once with following 
treatments:  
 G1 – VC (Distilled water, 10 mL/kg, 90 
days) - 15 animals per sex 
 G2 – LMWGAL-TF-250 (LMWGAL-
TF, 250 mg/kg, 90 days) - 15 animals per 
sex 
 G3 –LMWGAL-TF-500 (LMWGAL-TF, 
500 mg/kg, 90 days) - 15 animals per sex 
 G4 - LMWGAL-TF-1000 (LMWGAL-
TF, 1000 mg/kg, 90 days) - 15 animals 
per sex 
 G1R – VC reversal group -VC-R - (Dis-
tilled water, 10 mL/kg, 119 days) - 10 
animals per sex 
 G4R – LMWGAL-TF-1000-Reversal 
group (LMWGAL-TF-1000-R (LMW-
GAL-TF, 1000 mg/kg for 90 days) fol-
lowed by (distilled water, 10 mL/kg 
(from day 91 to day 119) - 10 animals 
per sex 
All treated rats were observed daily for 
mortality and clinical signs during the 90-
day study period whereas reversal groups 
(G1R and G4R) were observed for up to day 
119 (Reversal period of 28 days). The eyes 
of control and all the treated dose group an-
imals were examined prior to the initiation of 
the dosing and on day 91 and 119 (for G1R 
and G4R) of the study. Eye examination was 
carried out using an ophthalmoscope (mini 
2000, HEINE Optotechnik, Herrsching, 
Germany) after induction of mydriasis with 
0.5 % solution of tropicamide. The body 
weight and feed consumption of each rat 
were recorded at weekly intervals throughout 
the study period. Towards the end of the ex-
posure period (day 91), functional observa-
tions (by grading different sensory reactivity 
to stimuli of different types (auditory, visual 
and proprioceptive stimuli), assessment of 
grip strength (digital grip strength meter (Co-
lumbus Instruments International, Columbus, 
OH, USA)) and motor activity measurement 
were performed. The animals were placed in 
metabolic cages overnight and urine excreted 
by each animal was collected on day 91 and 
on day 119 (G1R and G4R) of the study for 
urinalysis. The parameters for urinalysis in-
cluded: specific gravity, pH, occult blood, 
protein, bilirubin, ketones, glucose, nitrite, 
and urobilinogen. Using whole blood, hema-
tological and coagulation analyzes were car-
ried out. The parameters for hematological 
analysis included: red blood cell count 
(RBC), reticulocyte count, hemoglobin (Hb), 
hematocrit (HCT), mean corpuscular hemo-
globin (MCH), mean corpuscular hemoglo-
bin concentration (MCHC), mean corpuscu-
lar volume (MCV) and total leukocyte count 
(TLC), % cells in differential leukocyte 
count (DLC) including lymphocyte (L), 
monocyte (M), basophils (B), eosinophils 
(E), and Prothrombin time (PT). Additional-
ly, clinical chemistry was evaluated includ-
ing Blood Urea Nitrogen (BUN), Alanine 
Aminotransferase (ALT), Aspartate Ami-
notransferase (AST), Alkaline Phosphatase 
(ALP), Gamma Glutamyl Transferase 
(GGT), Creatine Phosphokinase (CK), Lac-
tate Dehydrogenase (LDH), Fasting plasma 
glucose (FPG), Calcium (CA), Phosphorus 
(P), Bilirubin, Albumin, creatinine (CR), So-
dium (Na), Potassium (K), Chlorine (Cl), 
Total cholesterol (TC), and Triglycerides 
(Trig). On day 91, all animals were eu-
thanized and underwent gross pathological 
examination for signs of toxicity via necrop-
sy. All organs, mucosa, body cavities, etc. 
were examined for gross pathological chang-
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es. Major organs and major endocrine glands 
(pituitary, adrenal, thymus, thyroid, sex, etc.) 
were weighed as absolute values and from 
that their relative values (i.e. percent of the 
body weight) were calculated. Tissue sam-
ples from selected organs (heart, kidney, liv-
er, lung, spleen, stomach, pancreas and skel-
etal muscle) from the VC (G1 and G1R) and 
1000 mg/kg (G4 and G4R) groups were pre-
served, fixed, and stained for histopathologi-
cal evaluation via light microscopy. The re-
maining tissues/organs were preserved in 
10 % neutral buffered formalin from control 
and different dose groups. 
 
Mutagenicity study 
Mutagenicity was evaluated by bacterial 
Reverse Mutation test (AMES test) was per-
formed in full compliance with the OECD 
guidelines for mutagenicity testing namely 
Test No. 471 (Organisation for Economic 
Co-operation and Development, 1997). As 
no significant cytotoxic effect was observed, 
the five highest doses were then used in the 
subsequent mutagenicity evaluation. To 
evaluate mutagenicity, five strains of histi-
dine-dependent Salmonella typhimurium 
(TA97a, TA98, TA100, TA1535 and 
TA102) were tested in triplicate at the five 
highest doses (5000.00, 1666.67, 555.55, 
185.18 and 61.72 µg/plate) of LMWGAL-
TF. Rat liver homogenate tested with muta-
gen 2-aminofluorene before use. Metabolic 
activation was performed using a cofactor 
supplemented post-mitochondrial fraction 
(S9 fraction). Positive controls (2-amino-
fluorene, 2-aminoanthracene, methyl metha-
nesulfonate, 4-Nitroquinolene-N-Oxide, dan-
thron, and sodium azide) with and without 
S9 activator and negative controls (VC and 
phosphate buffer) with and without S9 acti-
vator were included in the evaluation. This 
was done to ensure the test system was func-
tioning properly (positive controls) and to 
obtain baseline revertant frequencies for the 
various strains of bacteria used in the study 
(negative controls). The plates were counted 
after 48 h of incubation at 37° C. The muta-
genic activity of the test substance was con-
sidered for positive in case of increased con-
centration over the range tested and a repro-
ducible increase at one or more concentra-
tions in a number of revertant colonies per 
plate in at least one strain with or without 
metabolic activation system. The test sub-
stance was considered to be toxic if there 
was a decrease in the number of revertants 
and/or thinning or absence of background 
lawn. 
 
Statistical analysis 
Statistical analysis was performed using 
SPSS analysis program for windows Version 
17.0 (SPSS Inc, USA). All the data were 
checked for normality and values were rep-
resented as mean ± standard deviation (SD). 
Data of body weight and food intake was an-
alyzed by two-way ANOVA followed by 
unpaired ‘t’ test. Remaining parameters were 
analyzed by separate One way ANOVAs. 
Dunnett’s test was used to analyze the dif-
ferences between treated groups with respec-
tive VC groups (G2, G3, G4 v/s. G1 and 
G4R v/s.G1R). The value of P < 0.05 was 
considered to be statistically significant. 
 
RESULTS 
Acute oral toxicity (AOT) study 
There were not either deaths or treat-
ment-related clinical signs of toxicity ob-
served during the evaluation period nor was 
any weight loss observed in any animals. Fi-
nally, no treatment-related gross pathological 
changes were observed during necropsy. The 
results of this evaluation show that the single 
oral dose resulted in an LD50 of greater than 
2000 mg/kg of body weight.  
 
Repeated dose 90-day oral toxicity  
(Sub-chronic) study 
No mortality was observed in any of the 
groups during the 90-day evaluation period. 
There were no treatment-related clinical 
signs of toxicity or ophthalmoscopic or func-
tional abnormalities during the evaluation 
period. There were no abnormalities in func-
tional observation battery parameters during 
handling (piloerection, reaction to removal, 
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reaction to handling, palpebral closure, eye 
examinations, lacrimation, salivation, mu-
cous membrane) and open field test (appear-
ance, gait, mobility, arousal, respiration, ton-
ic or clonic or stereotype movement, vocali-
zation, rearing, urination, defecation). 
There were no statistically significant 
differences in average daily food consump-
tions in treatment groups as compared with 
respective VC groups during treatment or re-
versal period in male and female rats (Figure 
1). Body weights of male and female rats did 
not show significant difference during the 
treatment period (Table 1). However, 
LMWGAL-TF-1000-R groups showed sig-
nificant differences in body weights as com-
pared with corresponding VC groups (P < 
0.01 and P < 0.05 for male and female rats 
respectively) during reversal period.  
 
 
Figure 1: Effect of LMWGAL-TF on food consumption in (A) male and (B) female rats during 90 days 
repeated dose toxicity study. Data are expressed as mean ± Standard deviation (SD) 
 
 
Table 1: Effect of LMWGAL-TF on body weights (g) of rats during 90 days repeated dose toxicity 
study 
Days 
Group 
G1 G2 G3 G4 G1R G4R 
VC LMWGAL-TF-250 
LMWGAL-TF-
500 
LMWGAL-TF-
1000 VC-R 
LMWGAL-TF-
1000-R 
male rats 
0 89.93 ± 6.55 88.87 ± 5.31 89.31 ± 4.96 90.21 ± 4.95 89.06 ± 6.31 90.27 ± 4.28 
90 382.95 ± 11.55 380.27 ± 13.31 377.43 ± 11.8 347.34 ± 9.68 380.7 ± 10.89 355.68 ± 16.16 
119 - - - - 410.14 ± 7.28 390.10 ± 14.39**
female rats 
0 89.61 ± 7.02 87.89 ± 4.8 88.44 ± 4.84 89.23 ± 5.49 87.79 ± 6.13 90.16 ± 5.93 
90 261.94 ± 9.54 257.99 ± 7.84 255.88 ± 4.31 245.73 ± 8.91 262.31 ± 6.35 247.30 ± 7.56 
119 - - - - 283.18 ± 2.88 274.02 ± 9.37* 
Data was represented as Mean ± Standard Deviation (SD). Data was analyzed by unpaired ‘t’ test, * = P < 0.05, ** P < 0.01 as 
compared of respective VC groups. 
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Hematological (Table 2 and Table 3) and 
biochemical observations (Table 4 and Table 
5) and urinalysis were recorded in male and 
female rats. All the values hematological and 
biochemical values were within normal bio-
logical and laboratory limits and the differ-
ences between the values were not consistent 
with treatment doses or period of observation 
(treatment / reversal) and so not treatment 
specific. For example, in male rats, LMW-
GAL-TF-250 and LMWGAL-TF-500 group 
(but not LMWGAL-TF-1000) showed a 
significant decrease (P < 0.01) in % MCHC 
during the treatment period as compared 
with VC group. On the other hand, 
LMWGAL-TF-1000-R group showed signif-
icant increase in % MCHC (P < 0.01) and % 
MCH (P < 0.05) as compared with VC-R 
group. The HCT and RBC count did not 
change significantly between the treatment 
groups and VC in both sexes whereas signif-
icant decreases (P < 0.05) was found were 
found in LMWGAL-TF-1000 group as com-
pared with VC-R group in female rats. On 
the other hand, platelet count of LMWGAL-
TF-1000 group showed a significant increase 
(P < 0.05) as compared with VC group dur-
ing treatment period but showed no signifi-
cant change in LMWGAL-TF-1000-R group 
as compared to VC-R group in the reversal 
period in female rats. In case of blood bio-
chemical parameters, AST values showed a 
significant (P < 0.05) decrease in LMW-
GAL-TF-1000-R as compared to VC-R 
group in female rats but male rats showed no 
statistical difference in LMWGAL-TF treat-
ed groups with their respective VC groups. 
Similarly, values of electrolytes Ca, Na, K 
and Cl showed significant changes between 
LMWGAL-TF treated groups during treat-
ment and reversal group without consistent 
correlation with dose levels during treatment 
or reversal period. 
 
 
 
Table 2: Effect of LMWGAL-TF on hematological parameters during 90 days repeated dose toxicity 
study (male rats) 
Parameters 
G1 G2 G3 G4 G1R G4R 
VC LMWGAL-TF-250 
LMWGAL-TF-
500 
LMWGAL-TF-
1000 VC-R 
LMWGAL-TF-
1000-R 
Hb (g %) 15.71 ± 1.20 15.45 ± 0.81 15.17 ± 0.79 16.21 ± 0.95 15.42 ± 0.79 16.20 ± 0.98 
RBC (x106 /µL) 8.58 ± 0.70 8.57 ± 0.52 8.42 ± 0.54 8.92 ± 0.51 9.00 ± 0.52 9.04 ± 0.47 
Reticulocytes ( %) 1.67 ± 0.50 1.66 ± 0.49 1.67 ± 0.41 1.66 ± 0.42 1.58 ± 0.66 1.52 ± 0.33 
HCT (%) 43.07 ± 3.46 42.86 ± 2.17 42.21 ± 2.25 44.27 ± 2.63 44.26 ± 1.91 45.00 ± 2.11 
MCV (mm3) 50.24 ± 1.48 50.03 ± 1.48 50.18 ± 1.46 49.67 ± 1.75 49.26 ± 1.70 49.82 ± 1.64 
MCH (pg) 18.34 ± 0.59 18.02 ± 0.67 18.05 ± 0.61 18.19 ± 0.63 17.18 ± 0.66 17.94 ± 0.79* 
MCHC (%) 36.50 ± 0.47 36.01 ± 0.46** 35.95 ± 0.39** 36.66 ± 0.32 34.86 ± 0.72 35.98 ± 0.57**
Platelets (x 103 /µL) 447.73 ± 52.22 435.40 ± 51.06 424.80 ± 99.58 421.13 ± 77.27 434.20 ± 86.72 433.20 ± 33.63
TLC 11.64 ± 3.17 11.49 ± 2.92 10.91 ± 3.66 12.99 ± 3.73 9.30 ± 1.51 9.06 ± 2.57 
PT (sec) 14.73 ± 3.61 14.33 ± 3.92 15.07 ± 3.81 14.80 ± 3.69 14.60 ± 2.3 14.60 ± 3.05 
N (%) 21.33 ± 3.62 21.53 ± 3.62 21.73 ± 3.92 21.27 ± 3.84 20.60 ± 3.51 21.20 ± 3.56 
L (%) 75.47 ± 3.11 75.00 ± 3.36 75.13 ± 3.44 75.53 ± 3.36 75.80 ± 3.03 75.00 ± 3.54 
E (%) 1.07 ± 0.88 1.13 ± 0.74 1.00 ± 0.85 0.93 ± 0.80 1.00 ± 1.00 1.20 ± 0.84 
M (%) 2.13 ± 0.83 2.33 ± 0.90 2.13 ± 0.92 2.27 ± 0.70 2.60 ± 0.55 2.60 ± 1.14 
B (%) 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Data was represented as Mean ± Standard Deviation (SD), Data was analyzed by unpaired ‘t’ test, * = P < 0.05, ** P < 0.01 as 
compared to respective VC groups.   
Hb: Hemoglobin; RBC: Red Blood Corpuscles, HCT : Hematocrit, MCV: Mean Corpuscular Volume, MCH: Mean Corpuscular 
Hemoglobin, MCHC: Mean Corpuscular Hemoglobin Concentration, TLC: Total leukocyte (White Blood Corpuscles) count, PT.: 
Prothrombin time, N: Neutrophils, L : Lymphocytes, E: Eosinophils, M : Monocytes, B : Basophils  
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Table 3: Effect of LMWGAL-TF on hematological parameters during 90 days repeated dose toxicity 
study (female rats) 
Parameters 
G1 G2 G3 G4 G1R G4R 
VC LMWGAL-TF-250 
LMWGAL-TF-
500 
LMWGAL-TF-
1000 VC-R 
LMWGAL-TF-
1000-R 
Hb (g %) 16.13 ± 1.88 16.52 ± 1.41 16.10 ± 1.46 16.14 ± 1.11 17.06 ± 1.11 16.28 ± 0.41 
RBC (x106 /µL) 8.39 ± 0.92 8.55 ± 0.87 8.39 ± 0.89 8.45 ± 0.72 9.15 ± 0.81 8.51 ± 0.33* 
Reticulocytes (%) 1.63 ± 0.44 1.69 ± 0.34 1.61 ± 0.49 1.58 ± 0.37 1.36 ± 0.4 1.48 ± 0.50 
HCT (%) 43.88 ± 4.84 44.81 ± 3.70 43.91 ± 3.99 43.75 ± 2.70 45.96 ± 2.66 43.16 ± 1.49* 
MCV (mm3) 52.32 ± 1.91 52.49 ± 1.62 52.49 ± 2.88 51.87 ± 2.09 50.36 ± 2.49 50.74 ± 1.72 
MCH (pg) 19.23 ± 0.77 19.36 ± 0.58 19.27 ± 1.11 19.15 ± 0.77 18.68 ± 1.11 19.16 ± 0.65 
MCHC (%) 36.74 ± 0.33 36.87 ± 0.38 36.69 ± 0.38 36.88 ± 0.43 37.12 ± 0.77 37.72 ± 0.39 
Platelets (x 103 /µL) 361.33 ± 73.43 353.07 ± 80.43 366.07 ± 62.93 431.80 ± 77.68* 449.20 ± 65.75 417.8 ± 75.79 
TLC 10.45 ± 3.35 10.79 ± 4.68 9.57 ± 2.34 13.43 ± 4.53 9.44 ± 4.47 9.64 ± 3.51 
PT (sec) 15.67 ± 3.72 15.00 ± 2.98 14.53 ± 3.58 15.80 ± 3.00 16.00 ± 3.16 16.40 ± 3.65 
N (%) 21.33 ± 3.42 21.93 ± 3.22 21.40 ± 3.68 21.33 ± 3.48 21.80 ± 3.27 22.20 ± 3.42 
L (%) 75.53 ± 3.38 74.87 ± 2.67 75.53 ± 4.02 75.47 ± 2.95 74.80 ± 2.17 75.00 ± 3.00 
E (%) 1.00 ± 0.76 1.13 ± 0.83 1.00 ± 0.85 1.13 ± 0.83 1.00 ± 1.00 0.60 ± 0.89 
M (%) 2.13 ± 0.74 2.07 ± 0.80 2.07 ± 0.88 2.07 ± 0.80 2.40 ± 0.55 2.20 ± 1.10 
B (%) 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Data was represented as Mean ± Standard Deviation (SD), Data was analyzed by unpaired ‘t’ test, * = P < 0.05, as compared to 
respective VC groups   
Hb: Hemoglobin; RBC: Red Blood Corpuscles, HCT : Hematocrit, MCV: Mean Corpuscular Volume, MCH: Mean Corpuscular 
Hemoglobin, MCHC:Mean Corpuscular Hemoglobin Concentration, TLC: Total leukocyte count, PT.: Prothrombin time, N: Neu-
trophils, L : Lymphocytes, E: Eosinophils, M : Monocytes, B : Basophils. 
 
Table 4: Effect of LMWGAL-TF on blood biochemistry on during 90 days repeated dose toxicity study 
(male rats) 
Parameters 
G1 G2 G3 G4 G1R G4R 
VC LMWGAL-TF-250 
LMWGAL-TF-
500 
LMWGAL-TF-
1000 VC-R 
LMWGAL-TF-
1000-R 
Total Protein (g %) 7.48 ± 0.53 7.52 ± 0.66 7.74 ± 0.47 7.40 ± 0.56 7.58 ± 0.42 7.43 ± 0.35 
BUN (mg %) 35.27 ± 3.65 35.27 ± 5.06 34.93 ± 4.70 36.6 ± 4.01 37.6 ± 4.04 34.4 ± 2.07 
ALT(IU/L) 40.40 ± 5.59 42.33 ± 4.30 41.33 ± 5.73 41.47 ± 6.08 37.20 ± 6.72 37.40 ± 6.19 
AST (IU/L) 63.07 ± 3.01 62.13 ± 3.54 61.47 ± 4.58 63.00 ± 5.66 62.40 ± 5.59 62.40 ± 5.41 
ALP (IU/L) 70.00 ± 5.14 71.87 ± 4.98 71.73 ± 5.35 71.07 ± 6.15 71.60 ± 6.50 71.00 ± 6.28 
FPG (mg %) 98.87 ± 8.02 97.00 ± 7.29 94.20 ± 6.86 96.20 ± 7.49 95.00 ± 13.06 93.20 ± 8.56 
Ca (mg %) 2.25 ± 0.09 2.42 ± 0.11** 2.34 ± 0.08 2.08 ± 0.14** 2.22 ± 0.11 2.29 ± 0.16 
P (mg %) 4.27 ± 0.42 4.13 ± 0.39 4.15 ± 0.46 3.91 ± 0.52 4.36 ± 0.43 3.90 ± 0.36* 
GGT (U/L) 16.00 ± 5.20 15.00 ± 5.35 15.67 ± 3.27 14.33 ± 3.87 17.40 ± 4.04 16.60 ± 3.51 
Bilirubin (mg %) 0.65 ± 0.07 0.65 ± 0.08 0.64 ± 0.06 0.63 ± 0.08 0.59 ± 0.06 0.67 ± 0.06* 
Albumin (g %) 3.47 ± 0.31 3.49 ± 0.30 3.41 ± 0.39 3.43 ± 0.28 3.58 ± 0.37 3.63 ± 0.30 
CR (mg %) 0.96 ± 0.11 0.96 ± 0.09 0.94 ± 0.09 0.93 ± 0.07 0.87 ± 0.07 0.98 ± 0.1* 
CK (IU/L) 59.93 ± 4.77 61.93 ± 5.47 60.07 ± 5.35 61.73 ± 5.62 62.00 ± 5.39 57.80 ± 5.63 
Na (mmol/l) 139.31 ± 1.55 137.71 ± 1.47** 139.66 ± 1.52 143.12 ± 3.79** 137.34 ± 0.78 139.63 ± 1.96**
K (mmol/l) 4.79 ± 0.23 5.06 ± 0.33* 5.07 ± 0.29* 4.54 ± 0.26* 4.73 ± 0.23 4.55 ± 0.62 
Cl (mmol/l) 114.5 ± 2.60 110.06 ± 1.63** 113.33 ± 2.51 116.31 ± 6.32 110.16 ± 1.64 106.15 ± 3.91*
Cholesterol (mg %) 63.13 ± 5.05 63.87 ± 5.76 63.33 ± 6.04 62.27 ± 4.7 65.00 ± 3.32 64.20 ± 3.96 
Trig (mg %) 110.00 ± 9.01 108.80 ± 10.96 108.47 ± 9.26 111.20 ± 8.21 107.80 ± 6.76 110.20 ± 8.04 
LDH (IU/L) 367.20 ± 27.78 364.00 ± 28.83 364.93 ± 29.78 356.27 ± 31.61 356.80 ± 28.61 360.60 ± 28.77
Data was represented as Mean ± Standard Deviation (SD), Data was analyzed by unpaired ‘t’ test, * = P < 0.05, ** P < 0.01 as 
compared to respective VC groups.   
BUN : Blood Urea Nitrogen, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, ALP: Alkaline Phosphatase, 
FPG : Fasting plasma glucose, Ca: Calcium, P: Phosphorus, GGT : Gamma Glutamyl Transferase, CR: Creatinine, CK : Crea-
tine Phospho Kinase, LDH : Lactate De-Hydrogenase, Na: Sodium, K: Potassium, Cl: Chlorine, Trig: Triglycerides. 
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Table 5: Effect of LMWGAL-TF on blood biochemistry on during 90 days repeated dose toxicity study 
(female rats) 
Parameters 
G1 G2 G3 G4 G1R G4R 
VC LMWGAL-TF-250 
LMWGAL-TF-
500 
LMWGAL-TF-
1000 VC-R 
LMWGAL-TF-
1000-R 
Total Protein (g %) 7.64 ± 0.63 7.74 ± 0.43 7.56 ± 0.52 7.54 ± 0.57 7.49 ± 0.50 7.64 ± 0.37 
BUN (mg %) 35.73 ± 4.27 34.53 ± 4.27 38.73 ± 4.68 36.27 ± 4.42 32.80 ± 2.86 35.40 ± 3.58 
ALT(IU/L) 41.73 ± 5.62 38.53 ± 6.75 39.33 ± 6.50 39.00 ± 6.57 37.80 ± 5.85 40.40 ± 4.51 
AST (IU/L) 61.67 ± 6.43 60.67 ± 5.81 60.87 ± 4.98 61.00 ± 6.75 64.60 ± 4.04 58.40 ± 6.02* 
ALP (IU/L) 71.80 ± 5.99 71.53 ± 7.55 71.00 ± 7.26 69.73 ± 7.82 70.40 ± 4.45 74.80 ± 5.31 
FPG (mg %) 101.47 ± 7.64 97.53 ± 10.67 94.60 ± 9.72 95.40 ± 10.57 101.00 ± 6.78 99.00 ± 4.18 
Ca (mg %) 2.24 ± 0.11 2.34 ± 0.10* 2.44 ± 0.08** 2.43 ± 0.12** 2.51 ± 0.10 2.27 ± 0.12** 
P (mg %) 4.23 ± 0.56 4.04 ± 0.48 3.93 ± 0.55 4.06 ± 0.45 4.16 ± 0.51 3.84 ± 0.52 
GGT (U/L) 15.93 ± 4.77 14.20 ± 5.12 15.67 ± 4.34 16.53 ± 3.62 19.00 ± 5.00 13.20± 2.59* 
Bilirubin (mg %) 0.63 ± 0.06 0.63 ± 0.07 0.63 ± 0.08 0.69 ± 0.07 0.65 ± 0.05 0.68 ± 0.08 
Albumin (g %) 3.60 ± 0.31 3.51 ± 0.24 3.63 ± 0.35 3.56 ± 0.24 3.66 ± 0.38 3.53 ± 0.40 
CR (mg %) 0.97 ± 0.07 0.95 ± 0.10 0.99 ± 0.14 0.97 ± 0.08 0.93 ± 0.04 0.94 ± 0.05 
CK (IU/L) 62.00 ± 4.71 59.73 ± 3.67 59.27 ± 5.12 61.40 ± 4.12 61.40 ± 4.34 64.20 ± 4.87 
Na (mmol/l) 140.36 ± 1.10 138.92 ± 1.08** 138.68 ± 1.22** 139.43 ± 2.16 140.80 ± 2.41 139.92 ± 0.73 
K (mmol/l) 4.44 ± 0.25 4.71 ± 0.30* 5.12 ± 0.24** 4.90** ± 0.30 4.51 ± 0.30 4.37 ± 0.26 
Cl (mmol/l) 113.23 ± 2.40 112.18 ± 1.86 110.92 ± 1.92* 113.38 ± 3.06 105.82 ± 2.22 101.83 ± 1.65**
Cholesterol (mg %) 63.33 ± 5.45 64.67 ± 4.92 63.60 ± 5.89 63.47 ± 5.54 63.00 ± 3.81 63.60 ± 3.71 
Trig (mg %) 107.53 ± 6.33 105.27 ± 11.04 111.00 ± 9.13 108.53 ± 9.14 111.40 ± 10.11 111.40 ± 5.13 
LDH (IU/L) 367.73 ± 28.00 364.2 ± 23.80 359.93 ± 33.07 368.33 ± 20.81 345.40 ± 21.35 353.80 ± 17.81
Data was represented as Mean ± Standard Deviation (SD), Data was analyzed by unpaired ‘t’ test, * = P < 0.05, ** P < 0.01 as 
compared to respective VC groups.   
BUN : Blood Urea Nitrogen, ALT: Alanine Aminotransferase, AST: Aspartate Aminotransferase, ALP: Alkaline Phosphatase, 
FPG : Fasting plasma glucose, Ca: Calcium, P: Phosphorus, GGT : Gamma Glutamyl Transferase, CR: Creatinine, CK : Crea-
tine Phospho Kinase, Na: Sodium, K: Potassium, Cl: Chlorine, Trig: Triglycerides, LDH : Lactate De-Hydrogenase 
 
No treatment-related gross pathological 
changes were observed in any organs of the 
test animals during necropsy. The data of 
weights of organs in LMWGAL-TF treated 
rats during treatment and reversal period in 
male and female rats is presented (Table 6 
and Table 7). None of the LMWGAL-TF 
treated group show significant difference 
during treatment or reversal period as com-
pared with corresponding VC group. The 
finding from histological examination of sec-
tions of organs is presented in Table 8 and 
representative photomicrographs are present-
ed as Figure 2 and Figure 3. The changes ob-
served in both VC and LMWGAL-TF-1000 
treatment groups were similar and compara-
ble in both sexes and hence considered as in-
cidental, congenital, and spontaneous. Based 
on the results of present study, the no ob-
served adverse effect level (NOAEL) is 1000 
mg/kg per day (the highest dose level). 
Mutagenicity study 
The bacterial background lawn was com-
parable with that of the respective VC plate 
up to the highest concentration of 5000 µg/ 
plate. No substantial increases in the re-
vertant colony count in any of the five strains 
were reported at any of the test concentra-
tions in the presence or absence of metabolic 
activation (S9 mix). Positive controls result-
ed in significant increases in the revertant 
count. The spontaneous reversion rates in the 
negative and positive control were within the 
range of historical data. The biologically rel-
evant increase in the revertant counts was not 
observed in any of the five tester strains pre-
incubated with the LMWGAL-TF. LMW-
GAL-TF did not induce gene mutation by 
pair changes or frameshifts in the genome of 
strains used during the present study. 
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Table 6: Effect of LMWGAL-TF on organ weights (g) of during 90 days repeated dose toxicity study 
(male rats) 
Organ 
G1 G2 G3 G4 G1R G4R 
VC LMWGAL-TF-250 
LMWGAL-TF-
500 
LMWGAL-TF-
1000 VC-R 
LMWGAL-TF-
1000-R 
Brain 0.553 ± 0.023 0.549 ± 0.021 0.555 ± 0.029 0.567 ± 0.020 0.523 ± 0.038 0.538 ± 0.019 
Liver 2.821 ± 0.203 2.824 ± 0.223 2.775 ± 0.190 2.904 ± 0.183 3.120 ± 0.170 3.064 ± 0.189 
Kidneys 0.731 ± 0.049 0.720 ± 0.060 0.736 ± 0.064 0.744 ± 0.050 0.768 ± 0.038 0.736 ± 0.052 
Adrenals 0.014 ± 0.002 0.014 ± 0.002 0.0146 ± 0.001 0.015 ± 0.002 0.015 ± 0.001 0.015 ± 0.002 
Testes 0.838 ± 0.052 0.803 ± 0.051 0.820 ± 0.072 0.864 ± 0.044 0.921 ± 0.112 0.902 ± 0.059 
Heart 0.315 ± 0.033 0.318 ± 0.028 0.314 ± 0.021 0.331 ± 0.027 0.349 ± 0.019 0.332 ± 0.023 
Spleen 0.358 ± 0.050 0.363 ± 0.065 0.372 ± 0.085 0.388 ± 0.068 0.438 ± 0.042 0.420 ± 0.114 
Lungs 0.473 ± 0.067 0.438 ± 0.051 0.444 ± 0.065 0.470 ± 0.065 0.462 ± 0.060 0.484 ± 0.032 
Thymus 0.064 ± 0.018 0.063 ± 0.018 0.065 ± 0.014 0.066 ± 0.018 0.041 ± 0.008 0.045 ± 0.009 
Epididymis 0.349 ± 0.046 0.343 ± 0.046 0.378 ± 0.038 0.378 ± 0.032 0.348 ± 0.034 0.355 ± 0.030 
Data was represented as Mean ± Standard Deviation (SD), Data was analyzed by unpaired ‘t’ test,   
* = P < 0.05, ** P < 0.01 as compared to respective VC groups 
 
 
Table 7: Effect of LMWGAL-TF on organ weights (g) of during 90 days repeated dose toxicity study 
(female rats) 
Organ 
G1 G2 G3 G4 G1R G4R 
VC LMWGAL-TF-250 
LMWGAL-TF-
500 
LMWGAL-TF-
1000 VC-R 
LMWGAL-TF-
1000-R 
Brain 0.76 ± 0.036 0.748 ± 0.036 0.763 ± 0.024 0.783 ± 0.032 0.753 ± 0.039 0.771 ± 0.057 
Liver 3.239 ± 0.194 3.123 ± 0.304 3.183 ± 0.217 3.168 ± 0.221 3.124 ± 0.243 3.2 ± 0.16 
Kidneys 0.659 ± 0.052 0.637 ± 0.041 0.634 ± 0.053 0.658 ± 0.066 0.636 ± 0.048 0.614 ± 0.082 
Adrenals 0.0263 ± 0.0041 0.0253 ± 0.0041 0.0246 ± 0.0044 0.027 ± 0.0058 0.026 ± 0.002 0.025 ± 0.003 
Ovaries 0.037 ± 0.006 0.0368 ± 0.006 0.0345 ± 0.0062 0.0389 ± 0.0047 0.0323 ± 0.0069 0.0363 ± 0.0059
Heart 0.348 ± 0.026 0.336 ± 0.025 0.339 ± 0.03 0.358 ± 0.025 0.348 ± 0.023 0.331 ± 0.021 
Spleen 0.443 ± 0.078 0.439 ± 0.085 0.396 ± 0.054 0.459 ± 0.097 0.347 ± 0.077 0.354 ± 0.06 
Lungs 0.589 ± 0.071 0.593 ± 0.043 0.559 ± 0.065 0.628 ± 0.097 0.524 ± 0.042 0.535 ± 0.046 
Thymus 0.089 ± 0.03 0.095 ± 0.019 0.095 ± 0.025 0.101 ± 0.031 0.057 ± 0.016 0.062 ± 0.014 
Uterus 0.167 ± 0.067 0.159 ± 0.036 0.163 ± 0.034 0.153 ± 0.029 0.15 ± 0.022 0.163 ± 0.027 
Data was represented as Mean ± Standard Deviation (SD), Data was analyzed by unpaired ‘t’ test,   
* = P < 0.05, ** P < 0.01 as compared to respective VC groups. 
 
 
Table 8: Summary of histopathology findings 
Organ and findings 
Number of rats with abnormalities 
Male Female 
G1 G4 G1 G4 
VC LMWGAL-TF-1000 VC 
LMWGAL-
TF-1000 
Number of Animals 15 15 15 15 
Adrenals     
Dilation NAD NAD 3 1 
Aorta NAD NAD NAD NAD 
Brain     
Lymphocytic Infiltration 1 1 2 NAD 
Necrosis 1 2 1 1 
Caecum NAD NAD NAD NAD 
EXCLI Journal 2016;15:446-459 – ISSN 1611-2156 
Received: June 22, 2016, accepted: July 02, 2016, published: July 13, 2016 
 
 
 
455 
Organ and findings 
Number of rats with abnormalities 
Male Female 
G1 G4 G1 G4 
VC LMWGAL-TF-1000 VC 
LMWGAL-
TF-1000 
Colon NAD NAD NAD NAD 
Duodenum NAD NAD NAD NAD 
Epididymis NAD NAD   
Eyes NAD NAD NAD NAD 
Heart NAD NAD NAD NAD 
Ileum NAD NAD NAD NAD 
Jejunum NAD NAD NAD NAD 
Kidneys     
Lymphocyte Infiltration  NAD 1 1 1 
Necrosis NAD 1 1 1 
Liver     
Lymphocyte Infiltration  12 14 14 13 
Necrosis 3 2 0 2 
Lungs      
Pneumonitis 12 15 14 15 
Haemorrhages 8 12 11 8 
Histiocytosis 1 1 3 0 
Lymph Node      
Cyst NAD NAD 2 1 
Ovaries - - NAD NAD 
Skin  NAD NAD NAD NAD 
Oesophagus NAD NAD NAD NAD 
Pancreas     
Lymphocyte Infiltration NAD 1 NAD NAD 
Pituitary     
Cysts 2 1 NAD NAD 
Prostate NAD NAD   
Rectum NAD NAD NAD NAD 
Sciatic nerve NAD NAD NAD NAD 
Seminal vesicles  NAD NAD NAD NAD 
Skeletal muscle NAD NAD NAD NAD 
Spleen NAD NAD NAD NAD 
Spinal cord     
Lymphocyte Infiltration NAD 1 2 1 
Sternum with bone marrow NAD NAD NAD NAD 
Stomach NAD NAD NAD NAD 
Testes NAD NAD - - 
Trachea     
Lymphocytic Infiltration 11 6 9 8 
Thymus     
Haemorrhages 3 2 2 2 
Thyroid / Parathyroid     
Ultimobranchial Cysts 1 NAD 2 2 
Urinary Bladder NAD NAD NAD NAD 
Uterus     
Eosinophilic infiltration - - 15 12 
Dilatation - - 3 2 
NAD = No Abnormality Detected 
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Figure 2: Effects of LMWGAL-TF on histological find-
ings of heart (A–D), kidney (E–H), liver (I–L) and lung 
(M–P) tissue in rats during 90- days repeated dose tox-
icity study. Photomicrographs from representative rats 
from respective groups: Male: VC (A, E, I and M), 
LMWGAL-TF-1000 (B, F, J and N), Female: VC (C, G, 
K and O) and LMWGAL-TF-1000 (D, H, L and P) 
(H&E stain) at 40X 
Figure 3: Effect of LMWGAL-TF on histological find-
ings of spleen (A–D), stomach (E–H) and pancreas 
(I–L) and skeletal muscle (M–P) tissue in rats during 
90 days repeated dose toxicity study. Photomicro-
graphs from representative rats from respective 
groups: Male: VC (A, E, I and M), LMWGAL-TF-
1000 (B, F, J and N), Female: VC (C, G, K and O) 
and LMWGAL-TF-1000 (D, H, L and P) (H&E stain) 
at 40X 
 
DISCUSSION 
In recent past, LMWGAL-TF has shown 
excellent potential for many therapeutic and 
nutritional applications for healthcare and 
sports nutrition area (Aswar et al., 2008; 
Kandhare et al., 2015; Visnagri et al., 2013; 
Wilborn et al., 2008). However, the safety 
and/or toxicology information on LMW-
GAL-TF has not been available. The present 
study evaluated LMWGAL-TF for acute and 
long term (90 days of daily administration) 
toxicity and mutagenicity potential in rats. 
Typically, safety studies on natural food 
supplements help to determine the dose lev-
els for short-term and long‑term repeated 
dose toxicity studies. The OECD guidelines 
are well-accepted standard for safety or tox-
icity assessments of medicinal. Therefore, 
the present study followed OECD guidelines.  
AOT data is considered valuable in es-
tablishing target organ toxicity. Repeated 
exposure of test substance over a long period 
of time has been utilized for the determina-
tion of adverse effects of a test substance 
qualitatively and quantitatively in laboratory 
animals (Joshua Allan et al., 2007). In the 
present investigation, single oral administra-
tion of LMWGAL-TF showed median lethal 
dose (LD50) level of 2000 mg/kg.  
In the OECD guidelines for subacute oral 
toxicity assessment, the adverse effect of the 
test substances has been determined and 
NOAEL is determined by using various he-
matological, biochemical and histopatholog-
ical analysis (Organisation for Economic Co-
operation and Development, 1998). Hence, 
we conducted sub-chronic 90-day repeated 
dose toxicity study. During the sub-chronic 
(90 days repeated dose) toxicity study, all 
rats survived until the scheduled euthanasia 
and no gross pathological alteration was 
found in the internal organs. A trend towards 
decrease (not statistically significant) in 
body weights in LMWGAL-TF groups that 
was observed during the present study is in 
line with the past reports of water-binding 
activity of oligosaccharides, slow gastric 
emptying, and increased bowel viscosity and 
subsequently decreased appetite and weight 
loss (Gentilcore et al., 2011). In the past, 
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many appetite suppressants were withdrawn 
from the market due to an increased risk of 
psychiatric disorders (Derosa and Maffioli, 
2012; Kang and Park, 2012). However, 
LMWGAL-TF treated rats showed no signif-
icant changes in food consumptions during 
the present study. In addition, no abnormali-
ties were observed in LMWGAL-TF group 
during treatment or reversal period during 
functional observation battery parameters 
during handling and open field test. Reversal 
groups (G1R and G4R) were incorporated to 
assess the reversibility of any potential tox-
icity that can progress after cessation of ad-
ministration. G4R group did not show ab-
normalities or deviations from normal in 
physiological values after cessation of treat-
ments in reversal groups Taken together, 
body weight loss (although not significant) 
in LMWGAL-TF treated groups indicate po-
tential for development of LMWGAL-TF as 
a safe product without central nervous sys-
tem side effects.  
Histopathological and biochemical find-
ings did not find any abnormalities or devia-
tions from normal physiological limits in 
LMWGAL-TF treated groups (G2, G3 and 
G4) compared to VC group at dose levels up 
to 1000 mg/kg. In the present study, LMW-
GAL-TF administration showed decreased 
MCH and MCHC without changes in Hb 
levels. However, these alterations were not 
sex- or dose-dependent and all values were 
within normal physiological range for rats 
(Wolford et al., 1986). Hence, the changes 
were not related to LMWGAL-TF treatment 
and dose of 1000 mg/kg (highest tested dose) 
was considered as no observed adverse event 
level (NOAEL) for the subchronic admin-
istration of LMWGAL-TF in rats.  
A biological assay to evaluate the muta-
genic potential of chemical compounds is 
AMES test (Mortelmans and Zeiger, 2000). 
LMWGAL-TF was evaluated over a broad 
concentration range (61.72–5000 µg/plate) 
and did not exhibit signs of significant muta-
genicity either in the presence or absence of 
a metabolic activator during the present 
study. 
An array of studies established a good 
correlation between the efficacy and safety 
evaluation of various plant-based products 
and/or phytochemicals via toxicological 
properties in rats (Delaney, 2007; Olson et 
al., 2000). A previous study carried out by a 
researcher showed the efficacy of oral ad-
ministration of LMWGAL-TF in an animal 
model of metabolic syndrome (Kandhare et 
al., 2015) and diabetes mellitus (Kamble et 
al., 2013) at 60 mg/kg/day (90-days) and 50 
mg/kg/day (for 21 days) respectively. The 
difference between preclinical efficacy dose 
(60 mg/kg) and NOAEL (1000 mg/kg) of 
LMWGAL-TF indicate excellent margin of 
safety. 
 
CONCLUSION 
The LD50 of LMWGAL-TF was found to 
be more than 2000 mg/kg. The NOAEL of 
LMWGAL-TF was found as 1000 mg/kg in 
both male and female rats. The present study 
indicated the safety for development of agent 
for clinical management of chronic disorders 
after appropriate clinical studies. 
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